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1. Introduction 
The increasing rate of human immunodeﬁ ciency virus 
(HIV) infection in many countries has had an impact on 
tuberculosis (TB) epidemiology. While TB prevalence has 
remained stable, TB incidence continues to rise, especially 
in countries most severely affected by the HIV epidemic as 
well as those facing political turmoil, migration, poverty and 
unemployment and where intravenous drug abuse is rampant. 
HIV is the most important known risk factor that promotes 
progression to active TB in people with Mycobacterium 
tuberculosis infection (TB/HIV A Clinical Manual 2004). 
The lifetime risk of tuberculosis in immunocompetent 
persons is 5% to 10%, but in HIV positive individuals, there 
is a 5% to 15% annual risk of developing active TB disease 
(Swaminathan et al 2000). WHO estimated 9.2 million 
new cases of TB globally in 2006 (139 per 100,000); of 
whom 7,09,000 (7.7%) were HIV positive (World Health 
Organization 2008). India, China, Indonesia, South Africa 
and Nigeria rank ﬁ rst to ﬁ fth in terms of incident TB cases. 
In India, there were 2.5 million people living with HIV 
and AIDS (PLWHA) at the end of 2007 while the incidence 
of TB was approximately 1.8 million cases per year (WHO 
Release 2007, RNTCP 2008). In a survey carried out among 
new tuberculosis patients by the Revised National TB 
control Program (RNTCP) in 2007, HIV sero-prevalence 
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The global impact of the converging dual epidemics of tuberculosis (TB) and human immunodeﬁ ciency virus (HIV) 
is one of the major public health challenges of our time. The World Health Organization (WHO) reports 9.2 million 
new cases of TB in 2006 of whom 7.7% were HIV-infected. Tuberculosis is the most common opportunistic infection 
in HIV-infected patients as well as the leading cause of death. Further, there has been an increase in rates of drug 
resistant tuberculosis, including multi-drug (MDRTB) and extensively drug resistant TB (XDRTB), which are difﬁ cult 
to treat and contribute to increased mortality. The diagnosis of TB is based on sputum smear microscopy, a 100-year 
old technique and chest radiography, which has problems of speciﬁ city. Extra-pulmonary, disseminated and sputum 
smear negative manifestations are more common in patients with advanced immunosuppression. Newer diagnostic 
tests are urgently required that are not only sensitive and speciﬁ c but easy to use in remote and resource-poor settings. 
Treatment of HIV-TB co-infection is complex and associated with high pill burden, overlapping drug toxicities, risk 
of immune reconstitution inﬂ ammatory syndrome (IRIS) and challenges related to adherence. From a programmatic 
point of view, screening of all HIV-infected persons for tuberculosis and vice-versa will help identify co-infected 
patients who require treatment for both infections. This requires good coordination and communication between the 
TB and AIDS control programs, in India.
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varied widely and ranged from 1% to 13.8% across the 15 
districts (Central TB Division, unpublished observations). 
Currently, it is not clear what role the HIV epidemic has 
played in the TB situation in India. If HIV prevalence in 
the community continues to increase, however, it could 
affect the TB control program, by decreasing cure rates and 
increasing mortality and recurrent TB. Further, appropriate 
management of patients with TB/HIV requires not only 
treating the tuberculosis but referring them for CD4 count 
testing and anti-retroviral treatment, if indicated.
2. Impact of HIV on TB manifestations
HIV infection is associated not only with an increased 
incidence of TB, but with altered clinical manifestations 
especially in the advanced stages. As HIV progresses, there 
is cutaneous anergy as well as impaired tissue containment 
of mycobacteria leading to widespread dissemination 
of mycobacteria. Figure 1 shows the increasing risk of 
tuberculosis as CD4 declines. In patients with latent TB 
infection, the risk of developing active disease is higher 
among recently infected persons compared to those with 
chronic infection but is several hundred-fold higher among 
persons who acquire HIV (ﬁ gure 2). Further, among persons 
with HIV infection, newly acquired TB infection can rapidly 
progress to active disease. 
It is clear that HIV infection acquired after TB infection 
is a signiﬁ cant risk factor for development of active TB-
- mainly due to its effects on the immune system. HIV is 
associated with decreased chemotaxis, defective granuloma 
formation and maintenance, impaired antigen processing 
and presentation as well as generalized loss of CD4+ T 
cells and selective clonal depletion of M-TB speciﬁ c CD4+ 
T lymphocytes (Lawn et al 2002). While TB can develop 
at any CD4 count, extrapulmonary and disseminated forms 
of the disease are more common as immunodeﬁ ciency 
increases. 
Recently, Miranda et al (2007) demonstrated an 80% 
reduction in incident TB in HAART treated compared 
to ART-naïve HIV-infected persons in Brazil. It is likely 
that as access to ART improves world-wide, there will be 
a reduction in new TB cases, though rates would still be 
higher than in the general population. 
3. Pulmonary TB
Pulmonary involvement occurs in about 75% of all HIV-
infected patients with TB. (Deivanayagam et al 2001; 
Ahmad and Shameem 2005; TB/HIV: A Clinical Manual 
2004). Unlike other opportunistic infections which have 
a selective range of CD4 in which the disease occurs, 
TB occurs throughout the course of HIV. The interaction 
between HIV and TB in persons coinfected with HIV and 
TB is bidirectional and synergistic. Clinical presentation 
however depends on the level of immnuosuppression. 
Typical manifestations are frequent in early HIV and atypical 
features begin to occur as the immunity declines with more 
frequent extra pulmonary manifestations ranging from 46 
to 79% (Kumarasamy et al 2005; Sharma et al 2005). An 
HIV positive individual with any of the following symptoms 
should be suspected of having TB and investigated further: 
cough of more than 2 weeks duration, fever lasting more than 
Figure 1. Risk of tuberculosis among HIV infected persons by CD4 + lymphocyte count (Antonucci et al 1995).
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2–3 weeks, weight loss, fatigue, listlessness, unexplained 
dyspnoea, chest pain, or hemoptysis. Accelerated weight 
loss deﬁ ned as greater than 10% weight loss in a month in
HIV has earned the name “slimming disease”. Differential 
diagnoses include bacterial or fungal pneumonias, 
Pneumocystis Jiroveci pneumonia (PCP), lymphoma and 
wasting syndrome. Cough with productive mucopurulent 
sputum is in favour of bacterial pneumonias including 
Figure 2. Risk of tuberculosis following tuberculous infection in individuals with chronic infection, recent infection and in those who 
acquire HIV infection (Rieder 1999).
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Figure 3. Clinical and immuno pathological course of HIV associated tuberculosis (De Cock et al 1992).
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TB whereas nonproductive cough with dyspnoea out of 
proportion to signs is in favour of PCP (TB/HIV A Clinical 
Manual 2004). 
4. Extra pulmonary TB
Extra pulmonary TB is the commonest cause of pyrexia 
of unknown origin (PUO) among HIV+ individuals in 
developing countries (Rupali et al 2003; Kejariwal et al 
2001). The most frequent extra pulmonary form of TB 
is involvement of the lymph nodes with cervical region 
being the commonest (Arora and Kumar 1999). Persistent 
generalized lymphadenopathy (PGL) simulates TB of the 
nodes. In PGL, nodes are symmetrical, asymptomatic and 
non-tender whereas in TB, lymph nodes are usually larger, 
asymmetric, painless and matted and maybe associated with 
constitutional symptoms or mediastinal/hilar adenopathy 
in the chest x-ray. Intrathoracic lymphadenopathy is not 
a feature of primary HIV syndrome and should always 
the raise the suspicion of TB or lymphoma. Lymph node 
involvement in HIV is characterized by poor granuloma 
formation with abundant AFB picked up by Ziehl Neelsen 
stain (Havlir and Barnes 1999) Diagnosis can be easily 
made by FNAC (done as an out-patient procedure) or by 
lymph node biopsy. While Mycobacterium tuberculosis 
accounts for most mycobacterial infections in India, a small 
proportion are due to non-tuberculous mycobacteria like 
M. avium intracellulare, M. fortuitum etc. – molecular or 
high performance liquid chromatography (HPLC) assays 
are required to differentiate between species (Singh et al 
2007).The other forms of extrapulmonary TB include pleural 
effusion, pericardial effusion, abdominal TB, TB meningitis 
and abdominal TB. Pleural effusion is usually unilateral and 
asymmetric, may be associated with parenchymal opacities. 
Intra cranial space occupying lesions are common in 
HIV-infected individuals: the differential diagnosis includes 
cerebral toxoplasmosis, tuberculoma, neurocysticercosis, 
cryptococcoma and lymphoma. In India, cryptococcal 
meningitis is the commonest form of meningitis followed 
by TB meningitis. A ﬁ nding that is strongly suggestive of 
disseminated TB is the detection of choroidal tubercles 
associated with miliary TB (Sahn and Neff 1974). Features 
of abdominal TB include hepatosplenomegaly with focal 
intra abdominal lymphadenopathy. Ascitis and omental 
thickening are less common in HIV (Fee et al 1995).
Mycobacteremia has been observed to be an important 
cause of PUO, particularly among patients with severe 
immunosuppression, but is difﬁ cult to diagnose as it requires 
facilities to perform blood culture using rapid culture 
techniques like BACTEC (Ramachandran et al 2002). In 
a study done in Africa, in patients with severe wasting at 
necropsy, nearly half had evidence of disseminated TB 
(Lucas et al 1994).
5. Investigations for diagnosis of TB
5.1 Sputum examination 
Three sputum specimens should be collected for patients 
suspected to have TB, including at least one overnight 
collection. Smear should be stained by Ziehl–Neelsen 
(conventional microscopy) or Auramine rhodamine 
(ﬂ uorescent microscopy). The advantages of ﬂ uorescence 
over light microscopy for the detection of pulmonary TB 
have been conﬁ rmed in a systematic review of 45 studies 
comparing the 2 methods, which found that ﬂ uorescence 
microscopy yielded an average increase in sensitivity of 10% 
with no loss of speciﬁ city (Steingart et al 2006). In situations 
where all 3 smears are negative, the RNTCP recommends a 
course of broad-spectrum antibiotics (avoiding quinolones) 
and repeating sputum smear examinations and performing a 
chest x-ray if the patient is still symptomatic for chest disease 
(Agarwal and Chauhan 2005). WHO recently proposed a 
modiﬁ ed algorithm for severely ill patients suggesting that 
anti-TB treatment can be started based on non-response to 
antibiotics and a chest x-ray, within 3-5 days (WHO smear 
negative algorithm 2006). However, this approach needs to 
be validated in a low HIV-prevalence country like India.
Culture (on Lowenstein-Jensen medium) is much more 
sensitive but takes 6-8 weeks and requires specialized 
laboratory facilities and trained staff. Automated liquid 
culture systems that detect bacterial CO2 production or 
O2 consumption with radiometric (BACTEC), ﬂ uorescent 
(MGIT), colorimetric (MB/BacT system) or pressure sensors 
(ESP culture system II) roughly halve the time to detection 
and are being evaluated for use in resource-poor settings 
(Williams-Bouyer et al 2000; Lee et al 2003; Gil-Setas et 
al 2004). Molecular assays have been developed for rapid 
detection of growth as well as species identiﬁ cation and 
drug susceptibility testing. The 3 most widely used assays, 
polymerase chain reaction (PCR) (Roche Diagnostics), 
transcription mediated ampliﬁ cation (Genprobe) and strand-
displacement ampliﬁ cation (Becton Dickinson) have shown 
excellent sensitivity, speciﬁ city and speed. Despite the clear 
advantages of these nucleic acid ampliﬁ cation tests over 
existing tests, especially for the rapid detection of smear 
negative disease, they have only limited use in TB endemic 
settings, primarily because of their cost and complexity. 
6. Chest radiography
While radiography is a commonly performed investigation, 
it must be remembered that patients with HIV co-infection 
may not have typical radiographic features of pulmonary 
tuberculosis. While patients with higher CD4 cells (>350 
cells/mm3) have radiographic abnormalities similar to their 
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HIV negative counterparts, patients with immunosuppression 
often have minimal or atypical ﬁ ndings (Long et al 1991). 
Diffuse pulmonary inﬁ ltrates/opacities are the dominant 
radiological presentation and cavitation is uncommon. 
Miliary pattern, mediastinal adenopathy and pleural effusion 
are more common and x-rays may be normal in 5-10% of 
HIV+ individuals (Swaminathan et al 2007). Differential 
diagnoses include PCP, non-tuberculous mycobacteria, 
nocardiosis, fungal infections and non-infective 
complications like lymphocytic interstitial pneumonitis. In 
the presence of a radiographic lesion suggestive of TB with 
negative sputum smears in an ambulatory patient, the best 
approach is to give a course of broad spectrum antibiotics 
(including co-trimoxazole) and repeat x-ray after 10-15 
days. Lack of improvement or deterioration would indicate 
TB (TB/HIV A Clinical Manual 2004).
7. Tuberculin skin (Mantoux) test
Tuberculin skin reactivity is dependant on cytokine mediated 
cellular immunity. It has been used as a diagnostic test for 
tuberculosis infection: an induration of 5 mm or more, in 
response to 1 TU of PPD-RT 23 tuberculin is usually taken 
as a positive response, in HIV-infected individuals. In TB 
high prevalence countries like India, tuberculin skin testing 
has no value in TB diagnosis, as a positive test indicates 
prior infection only and false negativity (due to anergy or 
other unknown factors) is common. In a recent analysis, 
we found that even with the cut off of 5 mm universally 
practiced for TB in HIV, in India the positive predictive 
value of a TST for TB was 48.8% for patients with CD4 < 
200 cells / mm3 and only 18.8 for patients with CD4 > 200 
cells /mm3 (Swaminathan et al 2008). Anergy testing using 
polyvalent antigens like candida, tetanus toxoid, or mumps 
has been given up now because it is highly unreliable. 
Overall, tuberculin testing is not useful in routine practice 
either for diagnosis of TB or latent TB infection. An initially 
negative PPD may become positive when IRS occurs and 
this has been suggested as a marker for IRS (Lawn et al 
2005).
8. Treatment of TB in HIV positive patients 
Current guidelines recommend that irrespective of HIV 
status, tuberculosis requires a minimum of 6 months of 
treatment with 4 drugs (including rifampin) in the intensive 
phase and 2 drugs in the continuation phase. Treatment 
consists of INH (H), Rifampin (RIF), Ethambutol (EMB) 
and Pyrazinamide (PYZ) for 2 months followed by INH 
and RIF for 4 months, given either daily or intermittently. In 
India, under the RNTCP, patients with newly diagnosed TB 
receive a 6-month thrice-weekly regimen (Cat I – 2EHRZ3/
4RH3) while those with relapse, default or failure receive 
an 8-month regimen (Cat II – 2SEHRZ3/1EHRZ3/5EHR3). 
Patients with smear negative pulmonary TB and localized 
extrapulmonary forms are treated with Cat III - 2HRZ3/
4RH3, however this regimen should be avoided in persons 
with HIV infection. 
While there have been no randomized clinical trials 
comparing daily and thrice-weekly treatment, observational 
studies have documented a higher risk of acquired rifamycin 
resistance when highly intermittent regimens are used in 
patients with advanced HIV disease (Nahid et al 2007). 
Factors that have been associated with higher failure and 
relapse rates along with increased mortality during treatment 
and follow-up are severe immunosuppression (CD4 < 100 
cells/mm3), highly intermittent rifampicin administration, 
lack of rifampicin in the regimen used and duration
of treatment of < 6 months. (Ackah et al 1995; Driver
et al 2001; Jindani et al 2004; Lawn et al 2007a, b; Nahid
et al 2007). The Tuberculosis Research Centre (TRC)
found, in a pilot study of patients with advanced HIV
and TB, a favourable response of 72% and an unfavourable 
response of 28% (including treatment failure and deaths) 
when treated with RNTCP Cat I regimen. Further,
37% of patients had died within 24 months of completing 
ATT. In general, HIV-infected patients with TB have 
higher mortality during and after treatment compared to 
HIV uninfected patients (Harries et al 2001; Nahid et al 
2007; Swaminathan et al 2008). An ongoing randomized 
clinical trial at TRC is examining the beneﬁ ts of a longer 
(9-month) regimen in reducing recurrences. Wider access 
to anti-retroviral treatment will help reduce mortality due 
to HIVTB.
9. Anti-retroviral treatment 
Currently available antiretroviral agents fall in the following 
groups of drugs: Nucleoside reverse transcriptase inhibitors 
(NRTIs), Non-nucleoside reverse transcriptase inhibitor 
(NNRTI’s), Protease inhibitors (PI), Integrase inhibitors, 
Chemokine receptor antagonists and Entry (fusion) 
inhibitors. HAART refers to the use of a combination of 
at least 3 antiretroviral (ART) drugs to form a maximally 
suppressive regimen. Regimens recommended for use in 
India for patients with concomitant TB are a combination 
of 2 NRTI’s with Efavirenz or less commonly Nevirapine. 
The NRTI combinations used commonly are Zidovudine 
with Lamivudine, Stavudine with Lamivudine, Tenofovir 
with Lamivudine, and rarely Abacavir with Lamivudine or 
Didanosine with Lamivudine (only the ﬁ rst two combinations 
are available in the national program) (National AIDS 
Control Organization 2007) There is some preliminary 
data to suggest that nevirapine can be safely given with 
rifampicin, but results of ongoing clinical trials are awaited 
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(Manosuthi et al 2006, 2008; Cohen et al 2008). Among 
the PI’s, nelﬁ navir, saquinavir, lopinavir and ritonavir can 
be used but additive hepatoxicity may occur with anti-TB 
drugs requiring close monitoring of liver function. (de Jong 
et al 2004).
Table 1 summarizes the WHO recommendations for 
timing of antiretroviral treatment initiation in HIVTB 
patients. In our experience, about 2/3rd of HIV infected 
individuals have a CD4 < 200 cells/mm3 when they present 
with TB. Hence, the earlier use of ART is likely to reduce 
mortality and morbidity in this group of patients. Table 2 
compares the advantages of early versus deferred ART in 
patients with TB. While the risks of IRIS and overlapping 
drug toxicities are present, the major advantage of early ART 
is the signiﬁ cant reduction in deaths.
10. Rifampicin –ART interactions and cytochrome 
P450 – 3A (CYP-3A) system
Rifamycins are unique in their ability to destroy both 
intracellular and intermittently and slowly growing TB 
bacilli and therefore form an indispensable component of 
anti-TB regimens. Non-Rifampicin containing regimens 
used to treat HIV-TB are associated with greater failure 
and relapse rates. (Jindani et al 2004; de Jong et al 2004). 
However, Rifamycins induce the CYP-3A enzyme system 
in the liver and intestinal wall, thereby increasing the 
metabolism of PI and non-nucleoside reverse transcriptase 
inhibitors (table 3). The effect is weaker with rifabutin than 
rifampin. Rifampin is metabolized through deacetylation 
and is not itself affected by the CYP-3A system. When 
rifampicin and antiretroviral drugs are given together, 
decreased trough levels may result, leading to therapeutic 
failure. Nevirapine levels are reduced by about 40–55%, 
efavirenz by 25% and delavaridine by 96% (McIlleron et 
al 2007). It has been suggested that the dose of Efavirenz 
be increased to 800 mg when administered along with 
Rifampicin, but this may not be necessary in subjects 
weighing < 50 kg. In India, Efavirenz is the preferred drug 
for use in HIV-TB co infected individuals at the standard 
600 mg dose. However, Nevirapine may be used in HIV-TB 
patients on concomitant ATT, when Efavirenz is contra-
indicated as in pregnancy, persons with psychiatric problems 
or due to toxicity. Alternatively, ATT may be modiﬁ ed with 
Rifabutin replacing rifampicin with the former given at a 
dose of 300 mg OD twice/thrice-weekly with nevirapine-
based ART.
11. Toxicity 
The overlapping toxicities due to the drugs commonly used 
for HIV associated TB are shown in table 4. Peripheral 
neuropathy which can be due to HIV per se can be further 
aggravated by Isoniazid, Stavudine and ddI. Almost all the 
Table 1. WHO recommendations for starting ART in HIV-TB patients on ATT (World Health Organization 2006)
CD4 cell count ART recommendations Timing of ART in relation to start of TB 
treatment
CD4 <200 cells/mm3 Recommend ARTa Between two and eight weeksb 
CD4 between 200 and 350 cells/mm3 Recommend ART After eight weeks
CD4 >350 cells/mm3 Defer ARTc Re-evaluate patient at eight weeks and at 
the end of TB treatment
Not available Recommend ARTd Between two and eight weeks
a An EFV-containing regimen is the preferred ﬁ rst-line regimen. Alternative ﬁ rst-line treatment regimens include NVP or triple NRTI 
(based on TDF or ABC) regimens. For NVP-containing regimens, ALT should be checked at 4, 8 and 12 weeks; treatment should be 
decided on the basis of symptoms thereafter.
bART should start as soon as TB treatment is tolerated, particularly in patients with severe immunosuppression.
cART should be started if other non-TB stage 3 or 4 events are present.
dFor some TB diagnoses that generally respond well to anti-TB therapy (ie, lymph node TB, uncomplicated pleural effusion), deferral 
of ART should be considered.
Table 2. Advantages of early vs deferred ART
Early ART Deferred ART
Early mortality due to TB is 
reduced.
Decrease in toxicity
Improvement in cure rate, 
reduction in relapses
Drug interaction reduced.
Drug resistance caused 
by malabsorption can be 
minimized.
Decrease in IRS
Prevents other OI’s 
simultaneously
ATT period can be used to 
lay a foundation for better 
adherence to ART
Period of Hospitalization 
reduced
Management of ATT toxicity 
is crucial for subsequent ART 
adherence
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drugs used are potentially hepatotoxic but the combination 
of Nevirapine and Rifampicin needs to be monitored closely. 
Thiacetazone should not be used in HIV+ individuals because 
of the risk of Stevens-Johnson syndrome. Co-trimoxazole 
can also produce cutaneous toxicity and has to be considered 
in the differential diagnosis of a skin rash. While Efavirenz 
can produce giddiness and sleep disturbances in the ﬁ rst 
few days/weeks of administration, rarely life-threatening 
psychiatric manifestations (depression, suicidal tendencies) 
can occur which require immediate termination of the drug. 
Most adverse effects of drugs are mild and can be managed 
symptomatically.
12. Anti-TB drug resistance 
While overall patterns of drug resistance to ﬁ rst line anti-
TB drugs are similar in HIV positive and negative patients, 
MDRTB is marginally higher (3-4%) in HIV positive 
patients with newly diagnosed TB (Swaminathan 2005). 
Rifampicin mono- resistance is more common in HIV 
infected patients and arises independently from mutations 
in drug susceptible strains. The mechanism is unclear but 
may be due to malabsorption of anti-TB drugs. Treatment 
for MDR-TB should ideally be based on drug susceptibility 
patterns and should employ at least 3-4 new drugs. The 
regimen should include an aminoglycoside and be given 
under direct observation. A typical regimen would consist of 
Inj Streptomycin or Kanamycin (three times a week) along 
with a combination of Oﬂ oxacin, Ethambutol, Ethionamide, 
Pyrazinamide with or without Cycloserine or PAS given 
daily. The treatment should be continued for 18-24 months 
(for at least 12 to 18 months after the cultures have become 
negative). Outcome of MDR –TB in HIV is poor. A study 
from South Africa in 2003 has revealed 41% mortality 
among HIV-infected MDR-TB cases. In the New York study 
in 1996, the situation was no less different with 72% of 
MDR –TB cases with HIV dying during treatment. (Finlay 
et al 2004; Park et al 1996).
Recently, strains of M. tuberculosis labelled as extensively 
drug resistant (XDR) TB have emerged and spread rapidly 
through HIV-infected populations leading to high mortality 
(Andrews et al 2007). XDRTB has been reported from India 
Table 3. Drug interactions of antiretroviral drugs with Rifampicin and Rifabutin
Rifampicin (normal daily dose 600 mg)
Rifabutin (daily, unless mentioned; normal 
daily dose 300 mg) 
NRTIs Normal rifampicin dose Normal rifabutin dose
NNRTIs
Efavirenz Efavirenz dose at 600mg Increase rifabutin dose to 450-600 mg
Normal efavirenz dose 
Nevirapine Probably can be used at normal nevirapine 
dose (more data required)
Normal dose each
Delavirdine NR (not recommended) NR
Protease inhibitors
Amprenavir / Nelﬁ navir NR Lower rifabutin dose to 150 mg
Atazanavir No data Lower rifabutin dose to 150 mg three times 
weekly
Saquinavir Can use with low-dose ritinavir “boost” Normal rifabutin dose
Ritonavir Use only with full-dose ritonavir Lower rifabutin dose to 150 mg two times 
weekly
Lopinavir / ritonavir Probably can be used with lopinavir / 
rotonavir dose increase to 400 / 400 mg or 
800 / 200 mg
Lower rifabutin dose to 150 mg three times 
weekly
Modiﬁ ed from de Jong et al (2004).
Table 4. Overlapping toxicities between ATT and ART
ATT ART
Hepatoxicity H, R, Z, NVP, NRTI’s
Neuropathy H ddI, d4T,
Hyperuricemia Z, E ddI
Neuropsyciatric disturbances H EFZ
GI symptoms All All, especially PI’s
Skin rashes R, Z NVP, EFZ, 
nelﬁ navir, Abacavir
Hematological R ZDV, PI’s
Perioral numbness Sm Amprenavir
Nephrotoxic R, E, Sm ddI
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also (Singh et al 2007; Thomas et al 2007), and basically 
is a result of mismanagement of TB. XDRTB is practically 
untreatable and the best approach, therefore, is to prevent its 
emergence, by strengthening and supporting the TB control 
program.
13. TB-IRIS 
Immune reconstitution inﬂ ammatory syndrome (IRIS) 
is deﬁ ned as transient worsening or appearance of new 
symptoms, signs or radiographic manifestations after 
initiation of HAART. Tuberculosis is the most frequent 
pathogen associated with IRIS, of which, lymph node 
enlargement is the commonest manifestation. In one study, 
the incidence of IRIS in TB alone was 2%, with HIV co-
infection it was 7%, and in those started on HAART it 
was 36% (Narita et al 1998). The median period of IRIS 
presentation is approximtely 4–6 weeks after starting ART, 
however IRIS has been observed as early as one week after 
starting ART. Risk factors include high viral load, very 
low CD4 and initiation of ART soon after TB diagnosis. In 
TB IRIS, fever is the most frequent symptom, along with 
worsening inﬁ ltrates on chest x-ray. Other manifestations 
include enlargement and liquefaction of lymph nodes, 
appearance of fresh crops of nodes, pleural effusion, 
pericardial effusion, ascites, subcutaneous abscesses, 
expanding CNS lesions and visceral lesions (Burman and 
Jones 2001).
Two types of IRIS are observed
(i)  An unmasking of a previously latent or sub-clinical 
infection precipitated by HAART – induced
immunologic changes occurring within 1–4 weeks 
of initiation of HAART (e.g.) MAC lymphadenitis, 
TB lymphadenitis and cryptococcal meningitis. 
(ii)  Augmented host response to antigens present in low 
amounts in tissues (paradoxial response).
Risk factors for TB –IRIS include early initiation of ART 
within two months of starting ATT, low CD4, presence of 
extrapulmonary TB especially of the central nervous system, 
disseminated TB and high viral load (Lawn et al 2007a, b). 
The pathogenesis of IRIS includes a sharp ampliﬁ cation 
of Interferon-gamma producing mycobacteria-speciﬁ c 
T cells along with an acute outpouring of Th1 cytokines 
(Borgarit 2006). It is likely that CD4 + T cells are not the 
only mediators of IRIS; therefore an increase in CD4 cell 
count with HAART does not necessarily correlate with the 
development of IRIS (Manabe et al 2007). Hypercalcemia is 
a strange but frequent manifestation in TB-related IRIS. It is 
probably related to increased production of 125 dihydroxy 
cholecalceferol in functioning granulomas. A simple way 
of demonstrating IRIS is restoration of DTH response to 
PPD. Interferon gamma secretion and cell mediated immune 
response to mycobacteria are restored leading to restoration 
of DTH skin test response to mycobacterial antigens. 
Thus HAART reverses the impact of HIV on the host 
granulomatous response to mycobacteria. But the rapidly 
compensating inﬂ ammatory response damages the tissues 
that characterize IRIS. (Lawn et al 2005)
The differential diagnoses include treatment failure, 
progression of TB, superadded infections and drug reaction. 
The best way to tackle IRS is to rule out and treat common, 
endemic causes of fever ﬁ rst. Most IRIS responds to non-
steroidal anti-inﬂ ammatory drugs (NSAIDS) along with 
continuation of ART. A course of steroids (Prednisolone 1 
mg/kg body weight) tapered over 4-6 weeks may be required 
when fever/constitutional symptoms prevail despite NSAID 
treatment or life-threatening symptoms occur. Thalidomide 
and pentoxyﬁ lline have also been tried as anti-inﬂ ammatory 
agents (Lawn et al 2005). Rarely, ART needs to be 
terminated.
14. Preventive therapy (Chemoprophylaxis)
for TB in India
Several randomized clinical trials in HIV-infected persons 
have shown that the incidence of TB can be reduced by 
40-60% by preventive therapy (Woldehanna and Volmink 
2004; Mohammed et al 2007). The standard regimen 
is Isoniazid for 12 months, though several short-course 
regimens like 2RZ and 3RH have been tried and found to 
be equivalent. However, adverse reactions tend to be higher 
with multi-drug regimens and the 2RZ regimen is no longer 
recommended because of a high incidence of hepatotoxicity, 
including several fatal cases in HIV un-infected persons 
(Narita et al 2002). Standard recommendations in USA, UK 
etc include giving preventive therapy to all PPD-positive (>5 
mm) HIV positive persons, after ruling out active TB. 
Presently, there is no national policy regarding TB 
preventive therapy for HIV positive persons in India. A 
clinical trial being conducted at the Tuberculosis Research 
Centre, Chennai is investigating two different regimens: a 6-
month regimen of ethambutol and INH vs. a 3-year regimen 
of INH alone, in order to establish the ideal duration of 
therapy. In a TB-endemic country like India, consideration 
must be given to providing preventive therapy to HIV-
infected persons regardless of Mantoux status.. This is 
because the prevalence of TB in the community is high with a 
constant risk of exposure as well as the fact that the Mantoux 
test has many pitfalls in interpretation. TB preventive therapy 
should form part of the care and support package for HIV+ 
persons that includes co-trimoxazole prophylaxis, nutritional 
counseling and supplementation and anti-retroviral treatment. 
It needs to be delivered through integrated counseling centres 
or anti-retroviral treatment centres, where HIV+ individuals 
are followed over the long term.
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15. Coordination between TB and AIDS
control programs
At the national level, there is a concerted effort to achieve 
coordination between the designated microscopy centre 
(DMC) of the RNTCP and the integrated counselling and 
testing centers (ICTC) of the HIV/AIDS control program. 
The objective is to promote early diagnosis and treatment 
of TB in HIV infected individuals and vice versa. All 
ICTC clients with suggestive symptoms are referred by the 
counselor to the nearest microscopy centre for investigations 
to rule out TB. In 2007, approximately 5% of all diagnosed 
TB cases in India came from ICTCs, demonstrating that these 
are excellent sites for active TB case ﬁ nding (RNTCP report 
2008). Further, the yield of cases was similar (approximately 
20%) from HIV infected and uninfected clients. Counselors 
need ongoing training to improve their knowledge about TB 
diagnosis and treatment. One of the programmatic limitations 
encountered is the lack of investigations for extrapulmonary 
TB at peripheral health facilities; another is the distance 
between DMCs and ICTCs in some districts. The system 
works much better when both are located in the same site.
Till a few months ago, TB patients were offered HIV 
testing only when the physician suspected HIV, due to co-
existing symptoms or signs (selective testing). Recently, the 
National AIDS Control Organization has taken a decision to 
routinely offer HIV testing to all diagnosed TB patients in 
the high-prevalence states. Our study on 4000 TB patients 
demonstrated that over 2/3rds were willing to undergo an 
HIV test and the major barrier to acceptance was patients 
not perceiving themselves to be at risk (Thomas et al 2007). 
If patients are counseled and explained the importance of 
having an HIV test, when they are diagnosed with TB, most 
will accept the test. 
With increasing availability of ART across the country, 
diagnosis of HIV is beneﬁ cial to the individual as he/she 
can be referred to the nearest ART centre for evaluation 
and initiation of antiretroviral treatment, if indicated. 
Tuberculosis clinics, therefore, form an important entry point 
for HIV diagnosis, care and support. Further, the counseling 
that patients receive as part of the process of testing will help 
prevent new infections in the future. Coordination and cross-
talk between these two government health programs is crucial 
not only to improve the outcome of HIV-infected TB patients 
but also to control the burden of tuberculosis in India.
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